Kamada (NASDAQ:KMDA) Reaches New 1-Year High – Here’s Why

Kamada Ltd. (NASDAQ:KMDA) shares reached a new 52-week high on Monday . The company traded as high as $8.50 and last traded at $8.72, with a volume of 1115207 shares changing hands. The stock had previously closed at $7.69.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of Kamada in a report on Friday, January 10th.

Kamada Stock Performance

The company’s 50-day simple moving average is $6.63 and its 200 day simple moving average is $5.93. The company has a market cap of $446.79 million, a PE ratio of 27.79, a PEG ratio of 0.88 and a beta of 0.99.

Institutional Trading of Kamada

A number of institutional investors have recently bought and sold shares of KMDA. JPMorgan Chase & Co. acquired a new stake in shares of Kamada during the fourth quarter worth about $67,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Kamada in the third quarter valued at approximately $77,000. Finally, Plato Investment Management Ltd acquired a new position in shares of Kamada in the 3rd quarter valued at $117,000. 20.38% of the stock is owned by hedge funds and other institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.